Brand semaglutide
Sold by Aspire Health · every brand semaglutide record
The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.
What you actually pay
Per month
At least $274
| Medication · Wegovy 0.25 mg/0.5 mg, 4 weeks (listed price; insurance may lower it) | $199 |
|---|---|
| Required membership | $75 |
| Consultation fee · Consultation fees compensate providers for reserved time, clinical review, administrative preparation, and related services. Consultation fees are generally non-refundable once a consultation, clinical review, asynchronous evaluation, or other provider service has occurred. | charged, amount not published |
A charge is disclosed without an amount, so this is a floor. We never count an unpriced charge as zero.
Price
| Term | Per month | Charged today |
|---|---|---|
| Wegovy 0.25 mg/0.5 mg, 4 weeks (listed price; insurance may lower it) “0.25 mg 4 weeks $199” source, read September 2, 2026 | Per month$199 | Charged today$199 |
| Wegovy all other doses, 4 weeks (listed price; insurance may lower it) “ALL OTHER DOSES 4 weeks $399” source, read September 2, 2026 | Per month$399 | Charged today$399 |
We earn nothing from this link. Aspire Health has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
- September 2, 2026 — $199
- September 3, 2026 — $199
- September 2, 2026 — Entry added to the register
Sourcing and terms
| Prescriber | Both |
|---|---|
| Cancellation | “You may cancel at any time by emailing info@aspirehealth.care. Cancellation is effective at the end of the then-current billing cycle. We do not provide refunds for partial billing periods except as required by law.” |
| Membership | Required. $75 per month. “The LoseIt Program is $75 monthly and provides ongoing medical oversight, follow-up visits, secure messaging, and care coordination to support your treatment safely and consistently. The program is billed monthly. Medication costs are billed separately and are based on your prescribed treatment plan. When compounded medication is prescribed, it is offered in 1-, 3-, or 6-month packages, billed upfront. Active enrollment in the LoseIt Program is required to continue medication therapy.” |
| Consult fee | Charged, and the amount is not published. Consultation fees compensate providers for reserved time, clinical review, administrative preparation, and related services. Consultation fees are generally non-refundable once a consultation, clinical review, asynchronous evaluation, or other provider service has occurred. |
Not yet checked: pharmacy and states.
Recorded from aspirehealth.care. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2, 2026 — Aspire Health states two different, unreconciled monthly non-medication fees: the semaglutide and tirzepatide product pages each say 'Monthly Medical Care: $49 — Includes provider visits, messaging, prescription management, and ongoing medical support. Medication priced separately (see tables above)', while the FAQ separately describes a 'LoseIt Program' at $75/month whose active enrollment 'is required to continue medication therapy.' Neither page mentions or reconciles the other figure. The membership entry above uses the $75 LoseIt Program figure since it is the one explicitly tied to required enrollment; the $49 'Monthly Medical Care' quote ('Monthly Medical Care: $49') from https://aspirehealth.care/tirzepatide-for-weight-loss/ and https://aspirehealth.care/semaglutide-for-medical-weight-management/ is flagged here rather than recorded a second time. Separately, https://aspirehealth.care/service-areas/ lists 49 state names (every state except Alabama) grouped as 'Western/Central/Eastern States,' but the page explains these are color-coded on an interactive map as 'Currently Licensed' vs. 'Coming Soon' — this text-extraction tool cannot read the map's color-coding, so which of the 49 are actually served today could not be confirmed; states.list is left empty rather than asserting all 49 as current coverage. The Wegovy/Zepbound dose tables are captioned 'Pricing varies based on insurance coverage. Patients should verify benefits directly with their insurance provider,' so it is unclear whether the listed dollar figures are a cash-pay price or already insurance-adjusted; recorded as-is with that caveat rather than labeled 'cash price'.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.